Disc Medicine reports Q1 EPS ($1.09), consensus ($1.00)

Cash and cash equivalents were $342.6M as of March 31, 2024, expected to fund operational plans into 2026. “The topline data from AURORA, presented in April, strengthened our belief that bitopertin is active. These data confirmed that bitopertin significantly reduced toxic PPIX in EPP patients and led to reduced phototoxic pain reactions and improved quality of life. We look forward to building upon this and sharing additional data from the AURORA and BEACON studies in June as we move towards regulatory interactions in the second half of the year,” said CEO John Quisel. “We also look forward to our additional readouts of updated data for DISC-0974 in anemia of myelofibrosis and initial data on DISC-3405 in healthy volunteers, both in June.”